IR@PKUHSC  > 北京大学第一临床医学院  > 药剂科
学科主题临床医学
Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis
Yang, Ting; Lu, Min; Ma, Lingyue; Zhou, Ying; Cui, Yimin
关键词Canagliflozin Metformin Type 2 Diabetes Meta-analysis
刊名EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
2015-11-01
DOI10.1007/s00228-015-1923-y
71期:11页:1325-1332
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]GLUCOSE COTRANSPORTER 2 ; BETA-CELL FUNCTION ; JAPANESE PATIENTS ; RANDOMIZED-TRIAL ; DOUBLE-BLIND ; GLYCEMIC CONTROL ; SAFETY ; INHIBITOR ; SULFONYLUREA ; SITAGLIPTIN
英文摘要

The aim of this study is to assess the efficacy and tolerability of canagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, added on to metformin in patients with type 2 diabetes mellitus (T2DM).

Literatures were searched from major electronic databases, as well as the Chinese State Food and Drug Administration and clinicaltrials.govfor unpublished studies. Only randomized controlled trials (RCTs) comparing canagliflozin with placebo in combination with metformin were included. Two reviewers independently selected studies, evaluated the risk of bias, and extracted data. The included RCTs were analyzed by the software RevMan 5.3 provided by the Cochrane Collaboration.

Six RCTs were chosen for the meta-analysis. Compared to placebo, canagliflozin produced absolute reduction in glycated hemoglobin A1c (HbA1c) (-0.66 % [-0.72 %, -0.61 %]). The proportion of patients who achieved target HbA1c was significantly greater in the canagliflozin-treated group (1.86 [1.69, 2.03]). Canagliflozin led to greater fasting plasma glucose (FPG) reduction of 1.49 mmol/L (100 mg/day) and 1.80 mmol/L (300 mg/day). Significant body weight loss of 2.09 % (100 mg/day) and 2.66 % (300 mg/day) with canagliflozin was observed. Canagliflozin was found to improve beta cell function in terms of homeostasis model assessment (HOMA2-%B) (15.59 % [12.84 %, 18.35 %]). Higher incidences of genital mycotic infection/female and pollakiuria (increased urine frequency) were noted with canagliflozin compared with placebo-controlled groups.

Canagliflozin is a potential option as an add-on to metformin based on its improvement in HbA1c, FPG, body weight, and beta cell function, but further studies are demanded to strengthen this evidence. Common adverse events (AEs) like genital mycotic infection/female and pollakiuria were identified.

语种英语
WOS记录号WOS:000363262000004
Citation statistics
Cited Times:9[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53408
Collection北京大学第一临床医学院_药剂科
作者单位Peking Univ, Dept Pharm, Hosp 1, Beijing 100034, Peoples R China
Recommended Citation
GB/T 7714
Yang, Ting,Lu, Min,Ma, Lingyue,et al. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,2015,71(11):1325-1332.
APA Yang, Ting,Lu, Min,Ma, Lingyue,Zhou, Ying,&Cui, Yimin.(2015).Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY,71(11),1325-1332.
MLA Yang, Ting,et al."Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis".EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 71.11(2015):1325-1332.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Yang, Ting]'s Articles
[Lu, Min]'s Articles
[Ma, Lingyue]'s Articles
百度学术
百度学术Similar articles in
[Yang, Ting]'s Articles
[Lu, Min]'s Articles
[Ma, Lingyue]'s Articles
必应学术
必应学术Similar articles in
[Yang, Ting]'s Articles
[Lu, Min]'s Articles
[Ma, Lingyue]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.